Related Experiment Video
Updated: Jun 5, 2026
06:45
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Overview of venous thromboembolism
José Ignacio Abad Rico1, Juan Vicente Llau Pitarch, Eduardo Rocha
1Trauma and Orthopaedic Surgery Department, Carlos Haya Regional University Hospital, Málaga, Spain.
Drugs
|December 18, 2010
Summary
Venous thromboembolism (VTE) is a significant cause of death, often preventable with anticoagulants. Increased adherence to guideline-recommended therapies like low molecular weight heparin (LMWH) can reduce mortality.
Area of Science:
- Medical Science
- Hematology
- Vascular Biology
Background:
- Thrombosis, or clot formation, occurs at sites of vessel wall injury, involving platelet activation and fibrin network formation.
- Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), posing a substantial mortality risk, particularly in Europe.
- Risk factors for VTE include surgery, trauma, immobilization, cancer, advanced age, obesity, and genetic predisposition.
Purpose of the Study:
- To review the established role of anticoagulants in the prevention and treatment of VTE.
- To highlight the importance of adhering to professional guidelines for anticoagulant therapy in VTE management.
- To emphasize the underutilization of thromboprophylaxis, especially in non-surgical patients, and advocate for improved adherence.
Main Methods:
- Review of existing literature and professional guidelines concerning VTE prevention and treatment.
- Analysis of anticoagulant therapies, including low molecular weight heparins (LMWH), unfractionated heparin (UFH), and fondaparinux.
- Discussion of factors influencing VTE development and the rationale for anticoagulant use.
Main Results:
- Anticoagulants are the primary treatment and prevention strategy for VTE, aiming to reduce morbidity, mortality, and long-term complications like post-thrombotic syndrome.
- Guidelines recommend specific anticoagulants based on patient risk profiles, with therapy duration varying accordingly.
- Despite evidence and recommendations, thromboprophylaxis remains underused, particularly in non-surgical settings.
Conclusions:
- Adherence to guideline-recommended anticoagulant therapies, such as outpatient LMWH, is crucial for reducing VTE-associated mortality.
- Improving the uptake of preventive anticoagulation strategies is essential for managing this preventable disease.
- Effective VTE management requires consistent application of evidence-based anticoagulant protocols.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...